Castle Biosciences Stock Price, News & Analysis

Castle Biosciences (CSTL) presented new findings on the performance of its DecisionDx®-Melanoma test at the Society of Surgical Oncology’s 2022 Conference. The study showed that DecisionDx-Melanoma, combined with the proprietary i31-SLNB algorithm, improved predictions of sentinel lymph node (SLN) positivity in melanoma patients compared to traditional T-stage criteria. It demonstrated an Area Under the Curve (AUC) of 0.89 for low-risk tumor identification versus 0.78 for T-stage, highlighting better precision. This advancement could lead to reduced unnecessary procedures and healthcare costs.

Castle Biosciences, Inc. (NASDAQ: CSTL) has announced that CEO Derek Maetzold and CFO Frank Stokes will present at two upcoming investor conferences: the 42nd Annual Cowen Health Care Conference on March 8, 2022, at 2:50 p.m. Eastern time, and the KeyBanc Capital Markets’ Virtual Life Sciences & MedTech Investor Forum on March 22, 2022, at 9:45 a.m. Eastern time. Live webcasts will be available on the company's website, with replays accessible for two weeks post-event. Castle Biosciences focuses on innovative diagnostic tests to enhance patient care.

Castle Biosciences (CSTL) reported a significant increase in full-year 2021 revenue, achieving $94.1 million, a 50% rise from 2020. The company's GEP testing volume grew by 55%, with expectations for 2022 revenue between $115-120 million. Key achievements include expanding the commercial team and successful acquisitions in dermatology and gastrointestinal testing markets, which collectively expand the U.S. addressable market by about $1 billion. However, the company faced a net loss of $31.3 million for 2021, highlighting ongoing challenges despite its operational growth.

Castle Biosciences (CSTL) will announce its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. A conference call and webcast will follow at 4:30 PM ET the same day, providing an opportunity for management to discuss the results and engage in a Q&A session. Investors can access the live event via phone or through the Company’s website. This release highlights the company's dedication to innovative diagnostics aimed at improving patient outcomes.

Castle Biosciences (NASDAQ: CSTL) announced that CEO Derek Maetzold and CFO Frank Stokes will present at the SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. ET. The presentation will be available via a live audio webcast on the company's website, with a replay accessible for two weeks after the event.

Castle focuses on innovative diagnostics, particularly for skin cancer. Their tests aim to provide personalized and actionable insights to improve treatment decisions and patient outcomes.

Castle Biosciences (CSTL) announced a collaboration with the National Cancer Institute (NCI) to link its DecisionDx-Melanoma test data with the SEER Program's melanoma case registry. Initial findings show that DecisionDx-Melanoma significantly improves overall survival rates in patients aged 65+ when compared to untested individuals. This data, presented at the 2022 Winter Clinical Dermatology Conference, indicates that patients tested with DecisionDx-Melanoma have a 34% lower risk of death, enhancing the test's clinical relevance. Future collaborations aim to include more recent data.

Castle Biosciences (NASDAQ: CSTL) will showcase its skin cancer diagnostic tests at Maui Derm for Dermatologists 2022 from January 24-28, 2022, in Maui, Hawaii. Key presentations include the integration of a 31-gene expression profile for melanoma risk assessment and the appropriate use of a 40-gene expression profile test for cutaneous squamous cell carcinoma. The DecisionDx-Melanoma and DecisionDx-SCC tests aim to enhance patient management by predicting metastatic risks. These tests have been validated in numerous studies, indicating their reliability in clinical settings.

Castle Biosciences (CSTL) announced a clinical performance study published in Future Oncology, showcasing the DecisionDx-SCC test's ability to independently assess metastasis risk in patients with cutaneous squamous cell carcinoma (SCC).

The study involved 420 cases and revealed significant stratification of risk, with metastasis rates of 6.6%, 20.0%, and 52.2% for Class 1, 2A, and 2B results, respectively. The findings suggest that integrating DecisionDx-SCC enhances risk prediction for individualized patient management.